Best Neurology Companies in Tel Aviv, Israel
The 36 best Neurology companies in Tel Aviv, Israel in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Prilenia.
Our analysis of 50 Neurology companies
$7.4b in tracked funding; 74% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Neurology companies in Tel Aviv
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Prilenia Developer of therapeutics for the treatment of neurogenerative diseases | $134M | 58 mo ago | Series B | Michael R Hayden Founder & CEO | 2018 | BugHerdApple iCloud MailMicrosoft 365+19 | — | — |
| 2 | BlueWind Medical Developer of neurostimulation device for the treatment of overactive bladder 50Patents top 39%Funding top 40%Innovation top 43%Tech top 46% All 9 signals ▾Patentstop 39% Fundingtop 40% Innovationtop 43% Techtop 46% Moattop 47% Markettop 50% Talentbottom 49% Globalbottom 40% Newsbottom 22% Patents: 73 patents matched (strict assignee match) · 23 filings since 2022 vs 38 in 2017-21 Funding: Raised $64.0M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 50/100 | $64M | 4 mo ago | Series B | Dan Lemaitre Chairman & CEO | 2010 | WordPress Block EditorWordPressMySQL+22 | 73 patents Patents concentrated in health & consumer products | 1 launch |
| 3 | RetiSpec Non-invasive eye scanner for early detection of Alzheimer’s Disease. 37Innovation top 38%Funding top 38%Product top 46%Tech bottom 43% All 6 signals ▾Innovationtop 38% Fundingtop 38% Producttop 46% Techbottom 43% Globalbottom 38% Marketbottom 34% Innovation: 2 product lines · Deep-tech classification: Tech Hardware Funding: Raised $17.0M across 3 rounds · 3 rounds over 9 yrs (0.3/yr) rank vs industry peers · Fliar Intelligence Index 37/100 | $17M | 25 mo ago | Series A | — | 2015 | — | — | — |
| 4 | Filterlex Medical Developer of an embolic protection device | $17M | 56 mo ago | Series B | Eyal Teichman Co-Founder | 2015 | — | — | — |
| 5 | Therapix Biosciences Developing cannabinoid-based therapies for CNS disorders | $13M | 66 mo ago | Acquired | Amitay Weiss CEO | 2014 | — | 36 patents Therapeutic formulations combining cannabinoids or opioids with N‑acylethanolamines and related biologics | — |
| 6 | PainReform Specialty pharmaceutical company that develops products for the treatment of pain 32Product top 24%Funding top 34%Growth top 35%Moat top 38% All 11 signals ▾Producttop 24% Fundingtop 34% Growthtop 35% Moattop 38% Newstop 43% Talentbottom 49% Innovationbottom 44% Techbottom 42% Patentsbottom 39% Globalbottom 35% Marketbottom 21% Product: 2 product launch events in 12 mo · 6 distinct product lines Funding: Raised $12.0M across 3 rounds · 3 rounds over 8 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 32/100 | $12M | 14 mo ago | Public | Michael Mulholland Chief Executive Officer | 2007 | WordPressMySQLPHP+16 | 22 patents Patents concentrated in health & consumer products | — |
| 7 | Perflow Medical Medical devices for neurovascular treatments | $12M | 103 mo ago | Series A | — | 2010 | — | 47 patents Patents concentrated in health & consumer products | — |
| 8 | Neurolief Wearable device for neurological and neuropsychiatric disorders 27Patents top 36%Talent top 38%Innovation top 39%Funding top 46% All 10 signals ▾Patentstop 36% Talenttop 38% Innovationtop 39% Fundingtop 46% Producttop 47% Moattop 47% Globalbottom 35% Marketbottom 28% Techbottom 26% Newsbottom 22% Patents: 55 patents matched (strict assignee match) · 18 filings since 2022 vs 29 in 2017-21 Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 27/100 | $11M | 5 mo ago | Series A | Shmuel Shany Co-Founder | 2012 | WordPressApple iCloud MailMicrosoft 365+14 | 55 patents Wearable transdermal neurostimulation headsets with integrated physiological sensing | 1 job opening |
| 9 | SMT Research and Development Embolic protection device | $10M | 185 mo ago | Deadpooled | Nikolaus Schweinert CTO & Founder | 2004 | — | — | — |
| 10 | Neurosteer Developer of a wearable band and a cloud platform for monitoring brain signals | $115K | 92 mo ago | Funding Raised | — | 2015 | DudaNginxAmazon Web Services+14 | 24 patents Closed-loop neurotechnology for brain activity monitoring and combined invasive/noninvasive stimulation | — |
Top 11 Neurology companies in Tel Aviv
#1
Series B · Herzliya, Tel Aviv · founded 2010 · 95 employees$64Mraised▾
Developer of neurostimulation device for the treatment of overactive bladder. The flagship product of the company is "Renova" a wireless device that delivers targeted electric stimulation to the nerve for the treatment of patients with an Overactive Bladder and associated symptoms of urinary urgency and frequency.
- May 2026Series B$47.8M
- May 2026Conventional Debt—
- May 2022Series B$64M
#2
Series A · Herzliya, Tel Aviv · founded 2012$11Mraised▾
Neurolief is focussed on developing a wearable platform technology for brain neuromodulation. It is developing a wearable device that enables the safe and effective treatment for neuro disorders such as migraine and depression without interfering with the patient's daily activities. As of September 2016, the device is in clinical development.
- Mar 2026Series A$6M
- Aug 2025Series A$5M
- 2015Seed—
#3
Public · Herzliya, Tel Aviv · founded 2007 · 6 employees$12Mraised▾
Painreform is a specialty pharmaceutical company that develops products for the treatment of pain. It is focused on reformulations of established pain drugs by applying unique technologies to prolong and enhance efficacy, reduce adverse effects and increase patients convenience as well as faster return of motor function. Its lead product PRF-110 provides a prolonged action of the local analgesic agent ropivacaine, a generic local analgesic drug. The company has applied for 2 PCT applications on its platform technology and on its lead product
- Jul 2025Post IPO$600K
- Mar 2021Post IPO$6M
- Jul 2018Series A$12M
#4
Series A · Tel Aviv, Tel Aviv · founded 2015 · 23 employees$17Mraised▾
RetiSpec was an early stage medical device startup developing a non-invasive eye scanner for early detection of Alzheimer’s Disease. The company was selected as the finalists at the MassChallenge Boston accelerator & had won 1st place at the JNF Lions-Den competition in Toronto & at the 2016 Partners Connected Health and AARP startup competition in Boston. As of Jan 2017, the company hasn't disclosed its product development details.
- Jul 2024Series A$10M
- Oct 2019Grant (prize money)$500K
- Jun 2017Grant (prize money)$50K
#5
Series B · Herzliya, Tel Aviv · founded 2018 · 39 employees$133.5Mraised▾
Developer of therapeutics for the treatment of neurogenerative diseases. It has developed its lead product Pridopidine, a sigma-1 receptor (S1R) agonist, for the treatment of multiple movement disorders and neurodegenerative diseases in adults and children. The compound is also shown to treat Huntington's disease (phase III), ALS, Parkinson’s disease levodopa-induced dyskinesia (PD-LID), and other conditions.
- Nov 2021Series B$43M
- Jun 2020Series A$62.5M
#6
Series B · Tel Aviv, Tel Aviv · founded 2015 · 11 employees$16.9Mraised▾
Developer of an embolic protection device. The CAPTIS device can be positioned in the aorta for reducing the risk of stroke and other complications during catheter-based structural heart procedures. The company is the winner of the best innovation award.
- Dec 2021Series B$7.9M
- Nov 2021Series A$6M
- Aug 2021Grant (prize money)$59K
- Jan 2020Grant (prize money)$61.3K
#7
Acquired · Givatayim, Tel Aviv · founded 2014$13Mraised▾
Therapix Biosciences is focused on developing drugs primarily for central nervous system (CNS) disorders. Using its IP portfolio of prescribed cannabinoid drugs and novel delivery systems, it is developing its pipeline. It currently has 2 development programs which include Brain Bright, a synthetic cannabinoid-based therapy for brain-related conditions, and Tourette Syndrome therapy based upon the entourage effect phenomenon among which the latter received an orphan drug designation.
- Mar 2021Post IPO$8.2M
- Jun 2020Post IPO$2.6M
- Apr 2019Post IPO$2.2M
#8
Series A · Tel Aviv, Tel Aviv · founded 2010 · 33 employees$12Mraised▾
Perflow Medical is focussed on developing medical devices for neurovascular treatments for stroke and other debilitating conditions. Its patented Cerebral Net (Controlled Radial Expansion Braids with Arterial Adjustability for Neurovascular Treatment) technological platform is based on the combination of design, development and manufacturing capabilities of braids and delivery systems. It is currently developing 3 products namely Stream, Bridge & Gate for neurovascular treatment devices used for thrombectomy, aneurysm neck bridging, and flow diversion.
- Feb 2018Series A$12M
- Apr 2014Seed—
#9
Deadpooled · Herzliya, Tel Aviv · founded 2004$10.5Mraised▾
SMT Research and Development has developed an embolic protection device, a filter to protect the brain from clots during minimally invasive procedures, such as Transcatheter Aortic Valve Implantation (TAVI) procedures and other complex percutaneous structural heart procedures. The company was deadpooled in June, 2013.
- Apr 2011Series A$10.5M
#10
Funding Raised · Herzliya, Tel Aviv · founded 2015 · 13 employees$115.3Kraised▾
Developer of a wearable band and a cloud platform for monitoring brain signals. The solution includes a cloud platform and a single bipolar sensor (Integrated into a headband). The sensor monitors and collects the data related to EEG brain waves which are later analyzed by using the cloud platform. They offer their services to enterprises and research institutes.
- Dec 2018Grant (prize money)$57.2K
- Sep 2018Grant (prize money)$58.1K
#11
Seed · Tel Aviv, Tel Aviv · founded 2021—raised▾
Developer of a portable ultrasound helmet for brain scans. It offers rapid and precise neurological diagnosis, such as strokes and traumatic brain injuries, with continuous real-time monitoring capabilities.
- Jun 2024Seed—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Neurology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Neuroscience & Neurotech is moving in Israel
A read on the academic research around Neuroscience & Neurotech — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 232 Israel-affiliated papers.
- Hebrew University of Jerusalem61
- Hadassah Medical Center55
- Tel Aviv University47
- Ben-Gurion University of the Negev24
- Hadassah Academic College22
- Deep brain stimulation10
- Subthalamic nucleus7
- Stimulation5
- Anesthesia5
- Parkinson's disease4
- Deep brain stimulation21→27
- Neurostimulation2→8
- Electrophysiology1→5
- Transcranial direct-current stimulation1→5
- Subthalamic nucleus12→15
- Neurostimulation1→5
- Essential tremor1→4
- Stimulation3→4
Where neurotech is researched across Israel
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.